Clinical Trial Detail

NCT ID NCT03316586
Title A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Cabozantinib + Nivolumab

Age Groups: adult senior

No variant requirements are available.